Previous 10 | Next 10 |
2024-03-28 13:42:43 ET More on Aldeyra Therapeutics Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects Seeking Alpha’s Quant Rating on Aldeyra ...
2024-03-27 10:45:02 ET AES Corp. (AES) AES is trading UP for the last 5 days, and it at trading at $16.90 with volume of 1,733,178 and a one day change of $0.26 (1.56%). AES Corp. has a 52-week low of 11.43 and a 52-week high of $25.74. The business's 50-day moving average price is ...
2024-03-27 02:09:28 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-03-25 12:17:33 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Landos Biopharma (NASDAQ: LABP ) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). AbbVie is acquiring ...
2024-03-25 11:05:30 ET More on Landos Biopharma Seeking Alpha’s Quant Rating on Landos Biopharma Historical earnings data for Landos Biopharma Financial information for Landos Biopharma Read the full article on Seeking Alpha For further details...
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics PR Newswire Allergan Aesthetics is raising the conversation on patient safety and ethical standards As part of its established Aesthetics-Ethics program...
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases PR Newswire Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill...
2024-03-24 00:46:24 ET Summary Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in ...
2024-03-22 18:01:23 ET More on AbbVie AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast AbbVie CEO marks final year...
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients PR Newswire - The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a p...
News, Short Squeeze, Breakout and More Instantly...
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults Canada NewsWire QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across...
2024-05-05 13:44:00 ET It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this was a long time coming, the market reacted as though it was unexpected: AbbVie's shares dropped once the ma...
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%....